Q-omics provides the consensus-scored NAALADL2-AS3 profile across patient tissues and cancer cell-line models. NAALADL2-AS3 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, NAALADL2-AS3 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, NAALADL2-AS3 RNA expression shows 8,187 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight PAAD, STAD, and HNSC as cancer lineages where NAALADL2-AS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAALADL2-AS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAALADL2-AS3 survival associations across molecular data types. NAALADL2-AS3 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAALADL2-AS3 RNA expression–survival associations across cancer types. High NAALADL2-AS3 expression shows unfavorable associations in PAAD, ACC, READ, LUSC, UCEC and OV. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for NAALADL2-AS3 RNA expression.
This table summarizes NAALADL2-AS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for NAALADL2-AS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAALADL2-AS3 shows lower tumor expression in COAD and THCA and higher tumor expression in STAD and LUAD. The STAD box plot shows higher NAALADL2-AS3 RNA expression in tumor versus normal tissue (log2 FC = +0.085, t-test p = .003).
This table shows molecular features associated with NAALADL2-AS3 in patient tissues and cancer cell lines. In patient samples, NAALADL2-AS3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
